CANAGLIFLOZIN, DAPAGLIFLOZIN and EMPAGLIFLOZIN as COMBINATION THERAPIES : a multiple prescribing statement - Pan Mersey APC Skip to main content Help with accessibility Skip to main navigation

CANAGLIFLOZIN, DAPAGLIFLOZIN and EMPAGLIFLOZIN as COMBINATION THERAPIES : a multiple prescribing statement

Last Updated: 01 November 2017

Body System: Endocrine System

Green

The Pan Mersey Area Prescribing Committee recommends the prescribing of CANAGLIFLOZIN, DAPAGLIFLOZIN and EMPAGLIFLOZIN as combination therapies for the treatment of type 2 diabetes in accordance with NICE guidance.